JP2024529839A5 - - Google Patents
Info
- Publication number
- JP2024529839A5 JP2024529839A5 JP2023580379A JP2023580379A JP2024529839A5 JP 2024529839 A5 JP2024529839 A5 JP 2024529839A5 JP 2023580379 A JP2023580379 A JP 2023580379A JP 2023580379 A JP2023580379 A JP 2023580379A JP 2024529839 A5 JP2024529839 A5 JP 2024529839A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163216446P | 2021-06-29 | 2021-06-29 | |
| US63/216,446 | 2021-06-29 | ||
| US202263320155P | 2022-03-15 | 2022-03-15 | |
| US63/320,155 | 2022-03-15 | ||
| PCT/US2022/035306 WO2023278438A1 (en) | 2021-06-29 | 2022-06-28 | Nlrp3 modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024529839A JP2024529839A (ja) | 2024-08-14 |
| JP2024529839A5 true JP2024529839A5 (https=) | 2025-06-30 |
| JPWO2023278438A5 JPWO2023278438A5 (https=) | 2025-06-30 |
Family
ID=84692056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023580379A Pending JP2024529839A (ja) | 2021-06-29 | 2022-06-28 | Ｎｌｒｐ３モジュレーター |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240327413A1 (https=) |
| EP (1) | EP4362946A4 (https=) |
| JP (1) | JP2024529839A (https=) |
| TW (1) | TW202319054A (https=) |
| WO (1) | WO2023278438A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| HRP20251513T1 (hr) | 2021-07-02 | 2026-01-02 | Astrazeneca Ab | Inhibitori inflamasoma nlrp3 |
| MX2024000984A (es) * | 2021-07-21 | 2024-06-19 | Nico Therapeutics Inc | Compuesto de piridazina anilado. |
| IL310992A (en) | 2021-08-25 | 2024-04-01 | Ptc Therapeutics Inc | NLRP3 inhibitors |
| CN118302417A (zh) * | 2021-08-25 | 2024-07-05 | Ptc医疗公司 | Nlrp3抑制剂 |
| US20240391881A1 (en) * | 2021-09-30 | 2024-11-28 | Origiant Pharmaceutical Co., Ltd. | Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative |
| CN116102535A (zh) | 2021-10-22 | 2023-05-12 | 索智生物科技（浙江）有限公司 | 一种含氮化合物、其制备方法及应用 |
| WO2023088856A1 (en) * | 2021-11-17 | 2023-05-25 | F. Hoffmann-La Roche Ag | Heterocyclic nlrp3 inhibitors |
| EP4499646A4 (en) * | 2022-03-31 | 2026-03-18 | Hangzhou Highlightll Pharmaceutical Co Ltd | NLRP3 Inflammasome Inhibitors |
| WO2024006559A1 (en) * | 2022-07-01 | 2024-01-04 | Neumora Therapeutics, Inc. | Modulators of nlrp3 inflammasome and related products and methods |
| EP4554945A1 (en) * | 2022-07-14 | 2025-05-21 | AC Immune SA | Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| CN120379995A (zh) * | 2022-12-27 | 2025-07-25 | 正大天晴药业集团股份有限公司 | 一种哒嗪稠芳环化合物及其用途 |
| WO2024157953A1 (ja) * | 2023-01-24 | 2024-08-02 | 第一三共株式会社 | 置換ベンゼン化合物 |
| CN120981462A (zh) * | 2023-01-31 | 2025-11-18 | 詹森药业有限公司 | 咪唑并[1,2-d][1,2,4]三嗪作为NLRP3抑制剂 |
| WO2024160694A1 (en) * | 2023-01-31 | 2024-08-08 | Janssen Pharmaceutica Nv | [1,2,4]TRIAZOLO[4,3-a]PYRIDINES AND [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS NLRP3 INHIBITORS |
| KR20250134147A (ko) | 2023-01-31 | 2025-09-09 | 얀센 파마슈티카 엔브이 | NLRP3 억제제로서의 피롤로[1,2-d][1,2,4]트리아진 및 피라졸로[1,5-d] [1,2,4]트리아진 |
| CN120659791A (zh) * | 2023-04-17 | 2025-09-16 | 上海拓界生物医药科技有限公司 | 稠合哒嗪类衍生物及其用途 |
| AU2024280075A1 (en) | 2023-06-02 | 2025-12-11 | Merck Sharp & Dohme Llc | 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2026057747A1 (en) | 2024-09-11 | 2026-03-19 | Ac Immune Sa | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9919957D0 (en) * | 1999-08-23 | 1999-10-27 | Merck Sharp & Dohme | Therapeutic agents |
| FR2868780B1 (fr) * | 2004-04-13 | 2008-10-17 | Sanofi Synthelabo | Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique |
| EP1745039A4 (en) * | 2004-05-08 | 2009-07-22 | Neurogen Corp | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES |
| WO2018221433A1 (ja) * | 2017-05-29 | 2018-12-06 | 第一三共株式会社 | ヘテロアリールアミン誘導体 |
| UY38687A (es) * | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| EP3999179A1 (en) * | 2019-07-17 | 2022-05-25 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| CN118302417A (zh) * | 2021-08-25 | 2024-07-05 | Ptc医疗公司 | Nlrp3抑制剂 |
-
2022
- 2022-06-28 US US18/574,530 patent/US20240327413A1/en active Pending
- 2022-06-28 EP EP22834059.2A patent/EP4362946A4/en active Pending
- 2022-06-28 WO PCT/US2022/035306 patent/WO2023278438A1/en not_active Ceased
- 2022-06-28 JP JP2023580379A patent/JP2024529839A/ja active Pending
- 2022-06-29 TW TW111124256A patent/TW202319054A/zh unknown